None of us can be happy about this memo that came out last November, showing how poorly this program is serving the American public.

The report calls into question the adequacy of the program's performance standards.

The challenges described in the memo are serious, and they must be addressed.

Excuse me, you are going to have to use your regulatory authority to do something that should have been said in the law by Congress.

This program is intended to address the threat of terrorism to the Nation's chemical facilities.

Thank you for yielding that time to me, Mr. Pallone. Madam Chair, I rise today in strong opposition to H.R. 1173. This bill is another Republican attempt to tear down and dismantle programs that provide health care in the United States…

It is the law, you are correct, that Yucca Mountain is the repository.

the frustrations in our inability to resolve this problem are huge.

There was no plan B. As the Blue Ribbon Commission explained, this decision was widely viewed as political and provoked strong opposition in Nevada.

In 1982, Congress passed the Nuclear Waste Policy Act, the Act sought to establish a fair and science-based process for selecting two nuclear fuel and high-level radioactive waste.

I agree, it is critical to retain that sunset provision so we have an opportunity to evaluate these questions, both the balance and the research questions as well.

It would be irresponsible to allow this legislation to become a vehicle for the wish lists of members seeking to move their own controversial bills.

Well, we all want these drugs on the market as fast as possible but I would be concerned about any proposal to remove FDA's ability to require clinical data when FDA thinks it is essential to assure that these drugs are safe and effective…

we have all been contacted by constituents. That is why I am here today.

I hope we would all agree that FDA should not take jobs into consideration when it is reviewing the safety and effectiveness of a new medicine.

We must reauthorize and establish these essential programs in a timely way so that FDA can do its job protecting the health and safety of American patients.

When we examine claims as serious as these, we must insist on data and on facts.

The drug and device user fee programs ensure that FDA gets critical dollars to allow the agency to complete its premarket review in a timely manner.

I want to thank Representatives Mike Rogers and Anna Eshoo, who are leading the reauthorization efforts on these important laws.

I believe that Americans deserve the confidence that the drugs they rely on will help them get better and not make them more sick.

Above all else, we must ensure that the prescriptions our children use are tested appropriately and deemed safe.

Thank you, Mr. Chairman.

If this were done on an aggressive schedule, a new route could be approved by October of 2012 at the earliest.

Now, we wanted to find out what interest the Koch Industries had.

Now, the Keystone XL tar sands pipeline poses substantial risks for Americans.